180 related articles for article (PubMed ID: 9615912)
21. Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients.
Reihnér E; Angelin B; Rudling M; Ewerth S; Björkhem I; Einarsson K
J Lipid Res; 1990 Dec; 31(12):2219-26. PubMed ID: 2090716
[TBL] [Abstract][Full Text] [Related]
22. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats.
Fujioka T; Nara F; Tsujita Y; Fukushige J; Fukami M; Kuroda M
Biochim Biophys Acta; 1995 Jan; 1254(1):7-12. PubMed ID: 7811749
[TBL] [Abstract][Full Text] [Related]
23. Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels.
Angelin B; Ewerth S; Einarsson K
J Lipid Res; 1983 Apr; 24(4):461-8. PubMed ID: 6854153
[TBL] [Abstract][Full Text] [Related]
24. Regulation of hepatic cholesterol metabolism in man.
Angelin B
Ann Med; 1991 Apr; 23(2):177-80. PubMed ID: 1906288
[TBL] [Abstract][Full Text] [Related]
25. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.
Nishizawa Y; Shoji T; Emoto M; Kawasaki K; Konishi T; Tabata T; Inoue T; Morii H
Clin Nephrol; 1995 Apr; 43(4):268-77. PubMed ID: 7606882
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
[TBL] [Abstract][Full Text] [Related]
27. Effect of withdrawal of pravastatin on biliary lipid composition in humans.
Muraca M; Baggio G; Vilei MT; Martini S; Cianci V; Crepaldi G
Atherosclerosis; 1996 Jun; 123(1-2):133-7. PubMed ID: 8782844
[TBL] [Abstract][Full Text] [Related]
28. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits.
Kurokawa J; Hayashi K; Toyota Y; Shingu T; Shiomi M; Kajiyama G
Biochim Biophys Acta; 1995 Oct; 1259(1):99-104. PubMed ID: 7492622
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
30. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
Richter WO; Jacob BG; Schwandt P
Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
[TBL] [Abstract][Full Text] [Related]
31. Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: relation to cholesterol gallstone disease and effects of cholic acid and chenodeoxycholic acid treatment.
Ahlberg J; Angelin B; Einarsson K
J Lipid Res; 1981 Mar; 22(3):410-22. PubMed ID: 7240966
[TBL] [Abstract][Full Text] [Related]
32. Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease.
Castro J; Amigo L; Miquel JF; Gälman C; Crovari F; Raddatz A; Zanlungo S; Jalil R; Rudling M; Nervi F
Hepatology; 2007 May; 45(5):1261-6. PubMed ID: 17464999
[TBL] [Abstract][Full Text] [Related]
33. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
34. Role of newly synthesized cholesterol or its metabolites on the regulation of bile acid biosynthesis after short-term biliary diversion in the rat.
Vlahcevic ZR; Pandak WM; Hylemon PB; Heuman DM
Hepatology; 1993 Sep; 18(3):660-8. PubMed ID: 8359807
[TBL] [Abstract][Full Text] [Related]
35. Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia.
Feillet C; Farnier M; Monnier LH; Percheron C; Colette C; Descomps B; Crastes De Paulet A
Atherosclerosis; 1995 Dec; 118(2):251-8. PubMed ID: 8770319
[TBL] [Abstract][Full Text] [Related]
36. The effect of vitamin C in high doses on plasma and biliary lipid composition in patients with cholesterol gallstones: prolongation of the nucleation time.
Gustafsson U; Wang FH; Axelson M; Kallner A; Sahlin S; Einarsson K
Eur J Clin Invest; 1997 May; 27(5):387-91. PubMed ID: 9179545
[TBL] [Abstract][Full Text] [Related]
37. Hepatic cholesterol metabolism in estrogen-treated men.
Angelin B; Olivecrona H; Reihnér E; Rudling M; Ståhlberg D; Eriksson M; Ewerth S; Henriksson P; Einarsson K
Gastroenterology; 1992 Nov; 103(5):1657-63. PubMed ID: 1426886
[TBL] [Abstract][Full Text] [Related]
38. The effect of pravastatin and atorvastatin on coenzyme Q10.
Bleske BE; Willis RA; Anthony M; Casselberry N; Datwani M; Uhley VE; Secontine SG; Shea MJ
Am Heart J; 2001 Aug; 142(2):E2. PubMed ID: 11479481
[TBL] [Abstract][Full Text] [Related]
39. Influence of newly synthesized cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption.
Bertolotti M; Zambianchi L; Carulli L; Simonini MS; Del Puppo M; Kienle MG; Loria P; Pinetti A; Carulli N
Hepatology; 2003 Oct; 38(4):939-46. PubMed ID: 14512881
[TBL] [Abstract][Full Text] [Related]
40. Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis.
Kolouchova G; Brcakova E; Hirsova P; Sispera L; Tomsik P; Cermanova J; Hyspler R; Slanarova M; Fuksa L; Lotkova H; Micuda S
J Gastroenterol Hepatol; 2011 Oct; 26(10):1544-51. PubMed ID: 21501227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
